13/01/2025
🧬 Normal Glypican-3 Serum Levels Do Not Eliminate the Risk of Hepatocellular Carcinoma
by Agnieszka Lembas, Tomasz Mikuła, Magdalena Suchacz, Joanna Kozłowska, Szymon Barczak, Barbara Badura, and Alicja Wiercińska-Drapało
This study investigates the role of glypican-3 (GPC3) as a biomarker for hepatocellular carcinoma (HCC) in patients with liver cirrhosis. Findings suggest that normal GPC3 levels do not rule out the risk of HCC, and a combined analysis with AFP and GGT shows limited diagnostic improvement.
📚 Read the full-length article: https://doi.org/10.21802/e-GMJ2024-A22